External factors influencing mesenchymal stem cell fate in vitro

Sisakhtnezhad, Sajjad; Alimoradi, Elham; Akrami, Hassan

doi:10.1016/j.ejcb.2016.11.003

Cited by 48 publications

(29 citation statements)

References 232 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Owing to tissue scarceness of primary MSCs, it is necessary to proliferate and expand them through cell culture. Their fate and function in culture is in uenced by various external factors, including the speci c cell source, donor age, plating density, passage number, plastic surface quality and external cytokines [33] .…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells regulated liver DX5- natural killer cells in acute-on-chronic liver failure

Xiong

Weng

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background :Acute-on-chronic liver failure (ACLF) is a severe, life-threatening syndrome with high mortality. Transplantation of Mesenchymal Stem Cells (MSCs) have been shown their efficacy in reducing mortality of ACLF patients in our clinical trials. Unveiling the underlying mechanism of action will improve clinical regime of ACLF. Methods: Flow cytometry was applied to assess frequency and phenotype of peripheral blood natural killer cell (NK) from HBV-ACLF patients during MSCs treatment. An acute-on-chronic liver failure mouse model was established by injection of carbon tetrachloride (CCL4) intraperitoneally. We used flow cytometry to characterize frequency, phenotype, proliferation, cytokine secretion and cell conjugation of NK cells from different sources before and after MSCs treatment. Microscopy was applied to investigate cell-cell contact. Results: Frequency of peripheral blood NK cells from HBV-ACLF patients was upregulated by MSCs infusion, which correlated with hepatitis remission. MSCs infusion rescued ACLF mice efficiently, coinciding with hepatitis remission, liver regeneration and NK cells frequency increase both in blood and liver. Strikingly, NKP46+ DX5-, instead of NKP46+ DX5+ liver NK cells responded well to MSCs. In vitro, MSCs were proved to promote the proliferation and GM-CSF secretion of NKP46+ DX5- liver NK cells specifically, which may be owing to their high cell-cell adhesion. Conclusions: Promoting NKP46+ DX5- liver NK cells proliferation and secreting GM-CSF maybe the new machinery of MSCs’ efficacy in ACLF.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells regulated liver DX5- natural killer cells in acute-on-chronic liver failure

Xiong

Weng

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Intravenous grafts of bmMSCs also prevent the onset of colitis and increase mice survival time via upregulating the expression of Foxp3+ regulatory T cells in mesenteric lymph nodes [88]. Upregulation in the activation of Th2 cells in UC and Th17/Th1 cells in Crohn's disease (CD) alongside decreased Treg levels are noted in IBD [89]. These stimulated T cells are highly apoptotic resilient due to the disparity of the proteins Bcl-x(L), Bcl-2, and Bax which are proapoptotic and antiapoptotic Bcl-2 family proteins [84].…”

Section: Therapeutic Utility Of Msc In Experimental Ibdmentioning

confidence: 99%

The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer

Ocansey

Qiu

Wang

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Approximately 18.1×106 new cases of cancer were recorded globally in 2018, out of which 9.6 million died. It is known that people who have Inflammatory Bowel Disease (IBD) turn to be prone to increased risks of developing colorectal cancer (CRC), which has global incident and mortality rates of 10.2% and 9.2%, respectively. Over the years, conventional treatments of IBD and its associated CRC have been noted to provide scarce desired results and often with severe complications. The introduction of biological agents as a better therapeutic approach has witnessed a great deal of success in both experimental and clinical models. With regard to mesenchymal stem cell (MSC) therapy, the ability of these cells to actively proliferate, undergo plastic differentiation, trigger strong immune regulation, exhibit low immunogenicity, and express abundant trophic factors has ensured their success in regenerative medicine and immune intervention therapies. Notwithstanding, MSC-based therapy is still confronted with some challenges including the likelihood of promoting tumor growth and metastasis, and possible overestimated therapeutic potentials. We review the success story of MSC-based therapy in IBD and its associated CRC as documented in experimental models and clinical trials, examining some of the challenges encountered and possible ways forward to producing an optimum MSC therapeutic imparts.

show abstract

“…Cell culture conditions are known to influence many aspects of stem cell biology, ranging from gene expression to proliferative behaviour and differentiation potential . The use of HPL instead of animal sera is a big step forward to eliminate the risk of infections transmitted by animal pathogens and immunoreactions due to xenogeneic proteins.…”

Section: Austriamentioning

confidence: 99%